Who is sponsoring NCT03198351?

NCT03198351 is sponsored by Sanofi.

What condition does NCT03198351 study?

NCT03198351 studies Multiple Sclerosis.

What drugs are being tested in NCT03198351?

Interventions: Teriflunomide (HMR1726).

What is the status of NCT03198351?

NCT03198351 is currently COMPLETED.

Last reviewed 2023-08-28 · How we verify

An Observational Study on Teriflunomide-exposed Pregnancies

NCT03198351 COMPLETED

Primary Objective: To evaluate any potential increase in the risk of major birth defects, in the first year of life, in teriflunomide-exposed pregnancies. Secondary Objective: To evaluate the potential effect of teriflunomide-exposure on other adverse pregnancy outcomes including any potential pattern of minor birth defects, spontaneous abortion, stillbirth, preterm delivery, small for gestational age at birth and at 1 year follow-up.

Details

Lead sponsor	Sanofi
Status	COMPLETED
Enrolment	220
Start date	Thu Apr 25 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Multiple Sclerosis

Interventions

Teriflunomide (HMR1726)

Countries

Canada, United States